<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="https://sms.carm.es/ricsmur/handle/123456789/17804">
<title>03.01. Investigación y comunicación científica</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/17804</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/28911"/>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/28907"/>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/28906"/>
<rdf:li rdf:resource="https://sms.carm.es/ricsmur/handle/123456789/28905"/>
</rdf:Seq>
</items>
<dc:date>2026-10-21T10:48:39Z</dc:date>
</channel>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/28911">
<title>BAX as a factor of susceptibility in hereditary nonpolyposis colorectal cancer</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/28911</link>
<description>BAX as a factor of susceptibility in hereditary nonpolyposis colorectal cancer
Ríos-Zambudio, Antonio; Rodríguez-González, José-Manuel; Parrilla-Paricio, Pascual; Carbonel, Pablo
</description>
<dc:date>2015-07-01T00:00:00Z</dc:date>
</item>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/28907">
<title>Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/28907</link>
<description>Flavonoid and lignan intake and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort
Molina-Montes, Esther; Sánchez, María-José; Zamora-Ros, Raul; Romieu, Isabelle; Scalbert, Augustin; Cross, Amanda-J; Lu, Yunxia; Riboli, Elio; Bueno-de-Mesquita, H-B(as); Wark, Petra-A; Obon-Santacana, Mireia; Duell, Eric-J; Kuehn, Tilman; Katzke, Verena; Travis, Ruth-C; Ye, Weimin; Sund, Malin; Naccarati, Alessio; Mattiello, Amalia; Krogh, Vittorio; Martorana, Caterina; Masala, Giovanna; Amiano, Pilar; Huerta-Castaño, José-María; Barricarte, Aurelio; Quiros, José-Ramon; Asli, Lene-Angell; Skeie, Guri; Weiderpass, Elisabete; Ericson, Ulrika; Sonestedt, Emily; Peeters, Petra-H; Overvad, Kim; Clemens, Matthias; Boeing, Heiner; Peppa, Eleni; Vidalis, Pavlos; Trichopoulou, Antonia; Khaw, Kay-Tee; Wareham, Nick; Olsen, Anja; Tjonneland, Anne; Boutroun-Rualt, Marie-Christine; Clavel-Chapelon, Francoise
Despite the potential cancer preventive effects of flavonoids and lignans, their ability to reduce pancreatic cancer risk has not been demonstrated in epidemiological studies. Our aim was to examine the association between dietary intakes of flavonoids and lignans and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 865 exocrine pancreatic cancer cases occurred after 11.3 years of follow-up of 477,309 cohort members. Dietary flavonoid and lignan intake was estimated through validated dietary questionnaires and the US Department of Agriculture (USDA) and Phenol Explorer databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were calculated using age, sex and center-stratified Cox proportional hazards models, adjusted for energy intake, body mass index (BMI), smoking, alcohol and diabetes status. Our results showed that neither overall dietary intake of flavonoids nor of lignans were associated with pancreatic cancer risk (multivariable-adjusted HR for a doubling of intake = 1.03, 95% CI: 0.95-1.11 and 1.02; 95% CI: 0.89-1.17, respectively). Statistically significant associations were also not observed by flavonoid subclasses. An inverse association between intake of flavanones and pancreatic cancer risk was apparent, without reaching statistical significance, in microscopically confirmed cases (HR for a doubling of intake = 0.96, 95% CI: 0.91-1.00). In conclusion, we did not observe an association between intake of flavonoids, flavonoid subclasses or lignans and pancreatic cancer risk in the EPIC cohort.
</description>
<dc:date>2016-10-01T00:00:00Z</dc:date>
</item>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/28906">
<title>Intraventricular injections of mesenchymal stem cells activate endogenous functional remyelination in a chronic demyelinating murine model</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/28906</link>
<description>Intraventricular injections of mesenchymal stem cells activate endogenous functional remyelination in a chronic demyelinating murine model
Cruz-Martínez, P; Pacheco-Torres, J; Geijo-Barrientos, E; Jones, J; González-Granero, S; Molina-Navarro, M-M; García-Verdugo, J-M; Martínez, Salvador
Current treatments for demyelinating diseases are generally only capable of ameliorating the symptoms, with little to no effect in decreasing myelin loss nor promoting functional recovery. Mesenchymal stem cells (MSCs) have been shown by many researchers to be a potential therapeutic tool in treating various neurodegenerative diseases, including demyelinating disorders. However, in the majority of the cases, the effect was only observed locally, in the area surrounding the graft. Thus, in order to achieve general remyelination in various brain structures simultaneously, bone marrow-derived MSCs were transplanted into the lateral ventricles (LVs) of the cuprizone murine model. In this manner, the cells may secrete soluble factors into the cerebrospinal fluid (CSF) and boost the endogenous oligodendrogenic potential of the subventricular zone (SVZ). As a result, oligodendrocyte progenitor cells (OPCs) were recruited within the corpus callosum (CC) over time, correlating with an increased myelin content. Electrophysiological studies, together with electron microscopy (EM) analysis, indicated that the newly formed myelin correctly enveloped the demyelinated axons and increased signal transduction through the CC. Moreover, increased neural stem progenitor cell (NSPC) proliferation was observed in the SVZ, possibly due to the tropic factors released by the MSCs. In conclusion, the findings of this study revealed that intraventricular injections of MSCs is a feasible method to elicit a paracrine effect in the oligodendrogenic niche of the SVZ, which is prone to respond to the factors secreted into the CSF and therefore promoting oligodendrogenesis and functional remyelination.
</description>
<dc:date>2016-05-12T00:00:00Z</dc:date>
</item>
<item rdf:about="https://sms.carm.es/ricsmur/handle/123456789/28905">
<title>Is Chronic Low Back Pain Associated with the Prevalence of Coronary Heart Disease when Genetic Susceptibility Is Considered? A Co-Twin Control Study of Spanish Twins</title>
<link>https://sms.carm.es/ricsmur/handle/123456789/28905</link>
<description>Is Chronic Low Back Pain Associated with the Prevalence of Coronary Heart Disease when Genetic Susceptibility Is Considered? A Co-Twin Control Study of Spanish Twins
Fernández, Matt; Refshauge, Kathryn-M; Pinheiro, Marina-B; Ferreira, Paulo-H; Ordoñana, Juan-Ramón; Sánchez-Romera, Juan-Francisco; Hartvigsen, Jan; Ferreira, Manuela-L; Simpson, Stephen-J; Hopper, John-L
OBJECTIVE: To investigate the chronic low back pain and coronary heart disease relationship, after adjusting for relevant confounders, including genetics. METHODS: In a cross-sectional design, 2148 twins were recruited from the Murcia Twin Registry, Spain. The exposure was chronic LBP and the outcomes were myocardial infarction and other coronary heart diseases-lifetime and in the last 2 years-based on standardized health-related questionnaires. First, logistic regression analysis investigated associations of the total sample followed by a matched co-twin control analyses, with all complete twin pairs discordant for chronic LBP utilised, separated for zygosity-dizygotic (DZ) and monozygotic (MZ) pairs, which adjusted for shared familial factors, including genetics. RESULTS: Chronic LBP pain is associated with lifetime myocardial infarction [odds ratio (OR) = 2.69, 95% confidence interval (CI) = 1.35-5.36], other coronary heart diseases over a lifetime (OR = 2.58, 95% CI: 1.69-3.93) and in the last two years (OR = 2.19, 95% CI: 1.33-3.60), while there was a borderline association with myocardial infarction in the last 2 years (OR = 2.64, 95% CI: 0.98-7.12). Although the magnitude of the association remained or increased in the co-twin control analyses, none reached statistical significance. CONCLUSION: Chronic LBP is associated with a higher prevalence of myocardial infarction and coronary heart disease. It is possible that this association remains even when controlling for genetics and early shared environment, although this should be investigated with larger samples of twins discordant for LBP.
</description>
<dc:date>2016-05-12T00:00:00Z</dc:date>
</item>
</rdf:RDF>
